{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:38:16Z","timestamp":1783960696019,"version":"3.55.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>The International Clinical Advisory Committee reviewed advances in our understanding of the clinicopathologic and biologic features of chronic lymphocytic leukaemia\/small lymphocytic lymphoma, B-cell prolymphocytic leukaemia, and mantle cell lymphoma since the revised 4th edition of the WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Discussions amongst pathologists, clinicians, and molecular geneticists around these diseases focussed on incorporating new knowledge into the next classification system. In this manuscript, we review these disease entities and incorporate results of these deliberations, including advances in our understanding of early lesions and transformation.\n<\/jats:p>","DOI":"10.1007\/s00428-022-03460-y","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:15:11Z","timestamp":1669900511000},"page":"131-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Chronic lymphocytic leukaemia\/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation"],"prefix":"10.1007","volume":"482","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-1340","authenticated-orcid":false,"given":"Birgitta","family":"Sander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-9793","authenticated-orcid":false,"given":"Elias","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-4067","authenticated-orcid":false,"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"issue":"21","key":"3460_CR1","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","volume":"131","author":"XS Puente","year":"2018","unstructured":"Puente XS, Jares P, Campo E (2018) Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood 131(21):2283\u20132296. https:\/\/doi.org\/10.1182\/blood-2017-10-764373","journal-title":"Blood"},{"issue":"11","key":"3460_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC et al (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140(11):1229\u20131253. https:\/\/doi.org\/10.1182\/blood.2022015851","journal-title":"Blood"},{"issue":"6","key":"3460_CR3","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood-2003-09-3277","volume":"103","author":"P Ghia","year":"2004","unstructured":"Ghia P, Prato G, Scielzo C, Stella S, Geuna M, Guida G et al (2004) Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 103(6):2337\u20132342. https:\/\/doi.org\/10.1182\/blood-2003-09-3277","journal-title":"Blood"},{"issue":"2","key":"3460_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1182\/blood.v100.2.635","volume":"100","author":"AC Rawstron","year":"2002","unstructured":"Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA et al (2002) Monoclonal B lymphocytes with the characteristics of \u201cindolent\u201d chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 100(2):635\u2013639. https:\/\/doi.org\/10.1182\/blood.v100.2.635","journal-title":"Blood"},{"issue":"6","key":"3460_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1056\/NEJMoa075290","volume":"359","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC, Bennett FL, O\u2019Connor SJ, Kwok M, Fenton JA, Plummer M et al (2008) Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 359(6):575\u2013583. https:\/\/doi.org\/10.1056\/NEJMoa075290","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3460_CR6","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1002\/cyto.b.20533","volume":"78","author":"AC Rawstron","year":"2010","unstructured":"Rawstron AC, Shanafelt T, Lanasa MC, Landgren O, Hanson C, Orfao A et al (2010) Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom 78(Suppl 1):S19-23. https:\/\/doi.org\/10.1002\/cyto.b.20533","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"3460_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","volume":"126","author":"P Strati","year":"2015","unstructured":"Strati P, Shanafelt TD (2015) Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126(4):454\u2013462. https:\/\/doi.org\/10.1182\/blood-2015-02-585059","journal-title":"Blood"},{"issue":"5","key":"3460_CR8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2017.177212","volume":"103","author":"A Agathangelidis","year":"2018","unstructured":"Agathangelidis A, Ljungstrom V, Scarfo L, Fazi C, Gounari M, Pandzic T et al (2018) Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. Haematologica 103(5):865\u2013873. https:\/\/doi.org\/10.3324\/haematol.2017.177212","journal-title":"Haematologica"},{"issue":"12","key":"3460_CR9","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.5858\/arpa.2020-0654-OA","volume":"145","author":"GK Habermehl","year":"2021","unstructured":"Habermehl GK, Durkin L, Hsi ED (2021) A tissue counterpart to monoclonal B-cell lymphocytosis. Arch Pathol Lab Med 145(12):1544\u20131551. https:\/\/doi.org\/10.5858\/arpa.2020-0654-OA","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"3460_CR10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3324\/haematol.2011.042333","volume":"96","author":"SE Gibson","year":"2011","unstructured":"Gibson SE, Swerdlow SH, Ferry JA, Surti U, Dal Cin P, Harris NL et al (2011) Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica 96(8):1144\u20131152. https:\/\/doi.org\/10.3324\/haematol.2011.042333","journal-title":"Haematologica"},{"issue":"12","key":"3460_CR11","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O (2021) Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol 96(12):1679\u20131705. https:\/\/doi.org\/10.1002\/ajh.26367","journal-title":"Am J Hematol"},{"issue":"3","key":"3460_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.beha.2019.06.001","volume":"32","author":"M Cross","year":"2019","unstructured":"Cross M, Dearden C (2019) B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol 32(3):217\u2013228. https:\/\/doi.org\/10.1016\/j.beha.2019.06.001","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"3460_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cyto.b.21595","volume":"94","author":"AC Rawstron","year":"2018","unstructured":"Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P et al (2018) Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom 94(1):121\u2013128. https:\/\/doi.org\/10.1002\/cyto.b.21595","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"3460_CR14","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","volume":"95","author":"E Gine","year":"2010","unstructured":"Gine E, Martinez A, Villamor N, Lopez-Guillermo A, Camos M, Martinez D et al (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95(9):1526\u20131533. https:\/\/doi.org\/10.3324\/haematol.2010.022277","journal-title":"Haematologica"},{"issue":"1","key":"3460_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1309\/AJCPIVKZRMPF93ET","volume":"138","author":"JF Gradowski","year":"2012","unstructured":"Gradowski JF, Sargent RL, Craig FE, Cieply K, Fuhrer K, Sherer C et al (2012) Chronic lymphocytic leukemia\/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression. Am J Clin Pathol 138(1):132\u2013139. https:\/\/doi.org\/10.1309\/AJCPIVKZRMPF93ET","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"3460_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ajcp\/aqz207","volume":"153","author":"N Patel","year":"2020","unstructured":"Patel N, Durkin L, Bodo J, Hsi ED (2020) Immunohistochemical expression of lymphoid enhancer binding factor 1 in CD5-positive marginal zone, lymphoplasmacytic, and follicular lymphomas. Am J Clin Pathol 153(5):646\u2013655. https:\/\/doi.org\/10.1093\/ajcp\/aqz207","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"3460_CR17","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F et al (2019) Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 133(11):1205\u20131216. https:\/\/doi.org\/10.1182\/blood-2018-09-873083","journal-title":"Blood"},{"issue":"3","key":"3460_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3324\/haematol.2020.274456","volume":"107","author":"S Ramos-Campoy","year":"2022","unstructured":"Ramos-Campoy S, Puiggros A, Bea S, Bougeon S, Larrayoz MJ, Costa D et al (2022) Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. Haematologica 107(3):593\u2013603. https:\/\/doi.org\/10.3324\/haematol.2020.274456","journal-title":"Haematologica"},{"issue":"6","key":"3460_CR19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"International CLLIPIwg","year":"2016","unstructured":"International CLLIPIwg (2016) An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17(6):779\u2013790. https:\/\/doi.org\/10.1016\/S1470-2045(16)30029-8","journal-title":"Lancet Oncol"},{"key":"3460_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01604-2","author":"A Agathangelidis","year":"2022","unstructured":"Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, Davis Z, Giudicelli V et al (2022) Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia. https:\/\/doi.org\/10.1038\/s41375-022-01604-2","journal-title":"Leukemia"},{"issue":"21","key":"3460_CR21","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood.2020008311","volume":"137","author":"F Nadeu","year":"2021","unstructured":"Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, Martin S et al (2021) IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood 137(21):2935\u20132946. https:\/\/doi.org\/10.1182\/blood.2020008311","journal-title":"Blood"},{"issue":"26","key":"3460_CR22","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910\u20131916. https:\/\/doi.org\/10.1056\/NEJM200012283432602","journal-title":"N Engl J Med"},{"issue":"10","key":"3460_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","volume":"17","author":"S O'Brien","year":"2016","unstructured":"O\u2019Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C et al (2016) Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 17(10):1409\u20131418. https:\/\/doi.org\/10.1016\/S1470-2045(16)30212-1","journal-title":"Lancet Oncol"},{"issue":"6","key":"3460_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T et al (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17(6):768\u2013778. https:\/\/doi.org\/10.1016\/S1470-2045(16)30019-5","journal-title":"Lancet Oncol"},{"issue":"17","key":"3460_CR25","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","volume":"127","author":"F Nadeu","year":"2016","unstructured":"Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M et al (2016) Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 127(17):2122\u20132130. https:\/\/doi.org\/10.1182\/blood-2015-07-659144","journal-title":"Blood"},{"issue":"20","key":"3460_CR26","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1158\/1078-0432.CCR-21-0701","volume":"27","author":"R Bomben","year":"2021","unstructured":"Bomben R, Rossi FM, Vit F, Bittolo T, D\u2019Agaro T, Zucchetto A et al (2021) TP53 mutations with low variant allele frequency predict short survival in chronic lymphocytic leukemia. Clin Cancer Res 27(20):5566\u20135575. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0701","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3460_CR27","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","volume":"32","author":"J Malcikova","year":"2018","unstructured":"Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T et al (2018) ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia 32(5):1070\u20131080. https:\/\/doi.org\/10.1038\/s41375-017-0007-7","journal-title":"Leukemia"},{"issue":"7574","key":"3460_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J et al (2015) Mutations driving CLL and their evolution in progression and relapse. Nature 526(7574):525\u2013530. https:\/\/doi.org\/10.1038\/nature15395","journal-title":"Nature"},{"issue":"7574","key":"3460_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero JI et al (2015) Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526(7574):519\u2013524. https:\/\/doi.org\/10.1038\/nature14666","journal-title":"Nature"},{"issue":"9","key":"3460_CR30","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.jmoldx.2020.06.004","volume":"22","author":"J Lee","year":"2020","unstructured":"Lee J, Wang YL (2020) Prognostic and predictive molecular biomarkers in chronic lymphocytic leukemia. J Mol Diagn 22(9):1114\u20131125. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.06.004","journal-title":"J Mol Diagn"},{"issue":"10","key":"3460_CR31","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00277-018-3350-5","volume":"97","author":"S Molica","year":"2018","unstructured":"Molica S, Giannarelli D, Mirabelli R, Levato L, Shanafelt TD (2018) Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis. Ann Hematol 97(10):2005\u20132008. https:\/\/doi.org\/10.1007\/s00277-018-3350-5","journal-title":"Ann Hematol"},{"issue":"11","key":"3460_CR32","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","volume":"123","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Kay NE, Shanafelt TD (2014) How we treat Richter syndrome. Blood 123(11):1647\u20131657. https:\/\/doi.org\/10.1182\/blood-2013-11-516229","journal-title":"Blood"},{"key":"3460_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","volume":"55","author":"W Xiao","year":"2016","unstructured":"Xiao W, Chen WW, Sorbara L, Davies-Hill T, Pittaluga S, Raffeld M et al (2016) Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. Hum Pathol 55:108\u2013116. https:\/\/doi.org\/10.1016\/j.humpath.2016.04.019","journal-title":"Hum Pathol"},{"issue":"6","key":"3460_CR34","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bjh.16748","volume":"190","author":"P Abrisqueta","year":"2020","unstructured":"Abrisqueta P, Delgado J, Alcoceba M, Oliveira AC, Loscertales J, Hernandez-Rivas JA et al (2020) Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol 190(6):854\u2013863. https:\/\/doi.org\/10.1111\/bjh.16748","journal-title":"Br J Haematol"},{"issue":"3","key":"3460_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2019.224121","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS et al (2020) Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica 105(3):765\u2013773. https:\/\/doi.org\/10.3324\/haematol.2019.224121","journal-title":"Haematologica"},{"issue":"25","key":"3460_CR36","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","volume":"131","author":"D Rossi","year":"2018","unstructured":"Rossi D, Spina V, Gaidano G (2018) Biology and treatment of Richter syndrome. Blood 131(25):2761\u20132772. https:\/\/doi.org\/10.1182\/blood-2018-01-791376","journal-title":"Blood"},{"issue":"6","key":"3460_CR37","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bjh.12458","volume":"162","author":"SA Parikh","year":"2013","unstructured":"Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W et al (2013) Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol 162(6):774\u2013782. https:\/\/doi.org\/10.1111\/bjh.12458","journal-title":"Br J Haematol"},{"issue":"1","key":"3460_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2141.2008.07152.x","volume":"142","author":"YO Huh","year":"2008","unstructured":"Huh YO, Lin KI, Vega F, Schlette E, Yin CC, Keating MJ et al (2008) MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 142(1):36\u201344. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07152.x","journal-title":"Br J Haematol"},{"issue":"1","key":"3460_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/asheducation-2018.1.256","volume":"2018","author":"W Ding","year":"2018","unstructured":"Ding W (2018) Richter transformation in the era of novel agents. Hematology Am Soc Hematol Educ Program 2018(1):256\u2013263. https:\/\/doi.org\/10.1182\/asheducation-2018.1.256","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"3460_CR40","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1111\/bjh.16948","volume":"191","author":"L Barnea Slonim","year":"2020","unstructured":"Barnea Slonim L, Ma S, Behdad A, Chen Q (2020) Pseudo-Richter transformation of chronic lymphocytic leukaemia\/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall. Br J Haematol 191(1):e22\u2013e25. https:\/\/doi.org\/10.1111\/bjh.16948","journal-title":"Br J Haematol"},{"key":"3460_CR41","doi-asserted-by":"publisher","unstructured":"Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M et al (2022) Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.\u00a0Nat Med. https:\/\/doi.org\/10.1038\/s41591-022-01927-8","DOI":"10.1038\/s41591-022-01927-8"},{"issue":"12","key":"3460_CR42","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood.2020008276","volume":"138","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S, Martines C, Porro F, Fortunati I, Bonato A, Dimishkovska M et al (2021) B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation. Blood 138(12):1053\u20131066. https:\/\/doi.org\/10.1182\/blood.2020008276","journal-title":"Blood"},{"issue":"15","key":"3460_CR43","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, O\u2019Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R et al (2006) Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24(15):2343\u20132351. https:\/\/doi.org\/10.1200\/JCO.2005.05.0187","journal-title":"J Clin Oncol"},{"key":"3460_CR44","doi-asserted-by":"publisher","unstructured":"King RL, Gupta A, Kurtin PJ, Ding W, Call TG, Rabe KG et al (2022) Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? Blood Cancer J.12(1):18. https:\/\/doi.org\/10.1038\/s41408-022-00616-6","DOI":"10.1038\/s41408-022-00616-6"},{"issue":"11","key":"3460_CR45","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.3324\/haematol.2020.256388","volume":"106","author":"DM Stephens","year":"2021","unstructured":"Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M et al (2021) Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica 106(11):2845\u20132852. https:\/\/doi.org\/10.3324\/haematol.2020.256388","journal-title":"Haematologica"},{"key":"3460_CR46","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). IARC (Lyon).285\u2013290."},{"issue":"7","key":"3460_CR47","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/sj.leu.2404238","volume":"20","author":"I Del Giudice","year":"2006","unstructured":"Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A et al (2006) IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia 20(7):1231\u20131237. https:\/\/doi.org\/10.1038\/sj.leu.2404238","journal-title":"Leukemia"},{"issue":"10","key":"3460_CR48","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1182\/blood.V88.10.3953.bloodjournal88103953","volume":"88","author":"F Davi","year":"1996","unstructured":"Davi F, Maloum K, Michel A, Pritsch O, Magnac C, Macintyre E et al (1996) High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia. Blood 88(10):3953\u20133961","journal-title":"Blood"},{"issue":"21","key":"3460_CR49","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1182\/blood.2019001187","volume":"134","author":"E Chapiro","year":"2019","unstructured":"Chapiro E, Pramil E, Diop M, Roos-Weil D, Dillard C, Gabillaud C et al (2019) Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood 134(21):1821\u20131831. https:\/\/doi.org\/10.1182\/blood.2019001187","journal-title":"Blood"},{"issue":"4","key":"3460_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1309\/PPK0-TJUK-1UAR-3194","volume":"115","author":"E Schlette","year":"2001","unstructured":"Schlette E, Bueso-Ramos C, Giles F, Glassman A, Hayes K, Medeiros LJ (2001) Mature B-cell leukemias with more than 55% prolymphocytes A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 115(4):571\u2013581. https:\/\/doi.org\/10.1309\/PPK0-TJUK-1UAR-3194","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"3460_CR51","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/blood-2013-10-533869","volume":"124","author":"VH van der Velden","year":"2014","unstructured":"van der Velden VH, Hoogeveen PG, de Ridder D, Schindler-van der Struijk M, van Zelm MC, Sanders M et al (2014) B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood 124(3):412\u2013419. https:\/\/doi.org\/10.1182\/blood-2013-10-533869","journal-title":"Blood"},{"issue":"9","key":"3460_CR52","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2018-07-862151","volume":"133","author":"D Martin-Garcia","year":"2019","unstructured":"Martin-Garcia D, Navarro A, Valdes-Mas R, Clot G, Gutierrez-Abril J, Prieto M et al (2019) CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1(-) mantle cell lymphoma. Blood 133(9):940\u2013951. https:\/\/doi.org\/10.1182\/blood-2018-07-862151","journal-title":"Blood"},{"issue":"8","key":"3460_CR53","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood.V90.8.3154","volume":"90","author":"MM Ott","year":"1997","unstructured":"Ott MM, Bartkova J, Bartek J, Durr A, Fischer L, Ott G et al (1997) Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood 90(8):3154\u20133159","journal-title":"Blood"},{"issue":"11","key":"3460_CR54","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.humpath.2012.01.003","volume":"43","author":"D Hoehn","year":"2012","unstructured":"Hoehn D, Miranda RN, Kanagal-Shamanna R, Lin P, Medeiros LJ (2012) Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation. Hum Pathol 43(11):1828\u20131838. https:\/\/doi.org\/10.1016\/j.humpath.2012.01.003","journal-title":"Hum Pathol"},{"key":"3460_CR55","doi-asserted-by":"publisher","unstructured":"Magnano L, Navarro A, Lopez-Guerra M, Clot G, Bea S, Bastidas G et al (2020) Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin? Haematologica.105(9):e484. https:\/\/doi.org\/10.3324\/haematol.2020.253062","DOI":"10.3324\/haematol.2020.253062"},{"issue":"10","key":"3460_CR56","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","volume":"28","author":"P Abrisqueta","year":"2017","unstructured":"Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD et al (2017) Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol 28(10):2489\u20132495. https:\/\/doi.org\/10.1093\/annonc\/mdx333","journal-title":"Ann Oncol"},{"issue":"3","key":"3460_CR57","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00428-015-1840-6","volume":"468","author":"B Sander","year":"2016","unstructured":"Sander B, Quintanilla-Martinez L, Ott G, Xerri L, Kuzu I, Chan JK et al (2016) Mantle cell lymphoma\u2013a spectrum from indolent to aggressive disease. Virchows Arch 468(3):245\u2013257. https:\/\/doi.org\/10.1007\/s00428-015-1840-6","journal-title":"Virchows Arch"},{"issue":"12","key":"3460_CR58","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/modpathol.2012.117","volume":"25","author":"P Adam","year":"2012","unstructured":"Adam P, Schiefer AI, Prill S, Henopp T, Quintanilla-Martinez L, Bosmuller HC et al (2012) Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues. Mod Pathol 25(12):1629\u20131636. https:\/\/doi.org\/10.1038\/modpathol.2012.117","journal-title":"Mod Pathol"},{"issue":"2","key":"3460_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3324\/haematol.2011.052621","volume":"97","author":"A Carvajal-Cuenca","year":"2012","unstructured":"Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY et al (2012) In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97(2):270\u2013278. https:\/\/doi.org\/10.3324\/haematol.2011.052621","journal-title":"Haematologica"},{"issue":"12","key":"3460_CR60","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.3109\/10428194.2015.1037759","volume":"56","author":"B Tandon","year":"2015","unstructured":"Tandon B, Swerdlow SH, Hasserjian RP, Surti U, Gibson SE (2015) Chronic lymphocytic leukemia\/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle? Leuk Lymphoma 56(12):3378\u20133386. https:\/\/doi.org\/10.3109\/10428194.2015.1037759","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3460_CR61","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/his.12009","volume":"62","author":"N Vogt","year":"2013","unstructured":"Vogt N, Klapper W (2013) Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. Histopathology 62(2):334\u2013342. https:\/\/doi.org\/10.1111\/his.12009","journal-title":"Histopathology"},{"issue":"8","key":"3460_CR62","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1097\/PAS.0000000000001278","volume":"43","author":"Y Miao","year":"2019","unstructured":"Miao Y, Lin P, Saksena A, Xu J, Wang M, Romaguera J et al (2019) CD5-negative mantle cell lymphoma: clinicopathologic correlations and outcome in 58 patients. Am J Surg Pathol 43(8):1052\u20131060. https:\/\/doi.org\/10.1097\/PAS.0000000000001278","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"3460_CR63","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/his.13286","volume":"71","author":"M Pizzi","year":"2017","unstructured":"Pizzi M, Agostinelli C, Righi S, Gazzola A, Mannu C, Galuppini F et al (2017) Aberrant expression of CD10 and BCL6 in mantle cell lymphoma. Histopathology 71(5):769\u2013777. https:\/\/doi.org\/10.1111\/his.13286","journal-title":"Histopathology"},{"issue":"12","key":"3460_CR64","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Martin-Garcia D, Clot G, Diaz-Navarro A, Duran-Ferrer M, Navarro A et al (2020) Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 136(12):1419\u20131432. https:\/\/doi.org\/10.1182\/blood.2020005289","journal-title":"Blood"},{"issue":"6","key":"3460_CR65","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/leu.2015.41","volume":"29","author":"K Yamamoto","year":"2015","unstructured":"Yamamoto K, Lee BJ, Li C, Dubois RL, Hobeika E, Bhagat G et al (2015) Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice. Leukemia 29(6):1414\u20131424. https:\/\/doi.org\/10.1038\/leu.2015.41","journal-title":"Leukemia"},{"issue":"1","key":"3460_CR66","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/gcc.22123","volume":"53","author":"C Sarkozy","year":"2014","unstructured":"Sarkozy C, Terre C, Jardin F, Radford I, Roche-Lestienne C, Penther D et al (2014) Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer 53(1):106\u2013116. https:\/\/doi.org\/10.1002\/gcc.22123","journal-title":"Genes Chromosomes Cancer"},{"issue":"13","key":"3460_CR67","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S et al (2020) Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv 4(13):2927\u20132938. https:\/\/doi.org\/10.1182\/bloodadvances.2019001350","journal-title":"Blood Adv"},{"key":"3460_CR68","doi-asserted-by":"publisher","unstructured":"Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y et al (2022) Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest.132(3). https:\/\/doi.org\/10.1172\/JCI153283","DOI":"10.1172\/JCI153283"},{"issue":"25","key":"3460_CR69","doi-asserted-by":"publisher","first-page":"38180","DOI":"10.18632\/oncotarget.9500","volume":"7","author":"C Wu","year":"2016","unstructured":"Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, Jurczak W et al (2016) Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations. Oncotarget 7(25):38180\u201338190. https:\/\/doi.org\/10.18632\/oncotarget.9500","journal-title":"Oncotarget"},{"issue":"2","key":"3460_CR70","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/modpathol.2017.135","volume":"31","author":"Z Hu","year":"2018","unstructured":"Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J et al (2018) CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol 31(2):327\u2013336. https:\/\/doi.org\/10.1038\/modpathol.2017.135","journal-title":"Mod Pathol"},{"key":"3460_CR71","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.humpath.2019.04.010","volume":"89","author":"A Saksena","year":"2019","unstructured":"Saksena A, Yin CC, Xu J, Li J, Zhou J, Wang SA et al (2019) CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. Hum Pathol 89:71\u201380. https:\/\/doi.org\/10.1016\/j.humpath.2019.04.010","journal-title":"Hum Pathol"},{"issue":"11","key":"3460_CR72","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/modpathol.2015.99","volume":"28","author":"I Ribera-Cortada","year":"2015","unstructured":"Ribera-Cortada I, Martinez D, Amador V, Royo C, Navarro A, Bea S et al (2015) Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. Mod Pathol 28(11):1435\u20131447. https:\/\/doi.org\/10.1038\/modpathol.2015.99","journal-title":"Mod Pathol"},{"issue":"2","key":"3460_CR73","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558\u2013565. https:\/\/doi.org\/10.1182\/blood-2007-06-095331","journal-title":"Blood"},{"issue":"1","key":"3460_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000302","volume":"4","author":"L Morello","year":"2020","unstructured":"Morello L, Rattotti S, Giordano L, Jerkeman M, van Meerten T, Krawczyk K et al (2020) Mantle cell lymphoma of mucosa-associated lymphoid tissue: a European mantle cell lymphoma network study. Hemasphere 4(1):e302. https:\/\/doi.org\/10.1097\/HS9.0000000000000302","journal-title":"Hemasphere"},{"issue":"4","key":"3460_CR75","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.3324\/haematol.2018.201350","volume":"104","author":"A Kumar","year":"2019","unstructured":"Kumar A, Ying Z, Alperovich A, Dogan A, Hamlin P, Moskowitz C et al (2019) Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica 104(4):e163\u2013e166. https:\/\/doi.org\/10.3324\/haematol.2018.201350","journal-title":"Haematologica"},{"issue":"18","key":"3460_CR76","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","volume":"119","author":"L Nygren","year":"2012","unstructured":"Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B (2012) Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 119(18):4215\u20134223. https:\/\/doi.org\/10.1182\/blood-2011-12-400580","journal-title":"Blood"},{"issue":"4","key":"3460_CR77","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G et al (2018) Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood 131(4):417\u2013420. https:\/\/doi.org\/10.1182\/blood-2017-07-797019","journal-title":"Blood"},{"issue":"17","key":"3460_CR78","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB et al (2017) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130(17):1903\u20131910. https:\/\/doi.org\/10.1182\/blood-2017-04-779736","journal-title":"Blood"},{"issue":"12","key":"3460_CR79","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C et al (2016) Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol 34(12):1386\u20131394. https:\/\/doi.org\/10.1200\/JCO.2015.63.8387","journal-title":"J Clin Oncol"},{"issue":"15","key":"3460_CR80","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","volume":"35","author":"DW Scott","year":"2017","unstructured":"Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D et al (2017) New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol 35(15):1668\u20131677. https:\/\/doi.org\/10.1200\/JCO.2016.70.7901","journal-title":"J Clin Oncol"},{"issue":"2","key":"3460_CR81","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bjh.15518","volume":"183","author":"H Holte","year":"2018","unstructured":"Holte H, Beiske K, Boyle M, Troen G, Blaker YN, Myklebust J et al (2018) The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. Br J Haematol 183(2):225\u2013234. https:\/\/doi.org\/10.1111\/bjh.15518","journal-title":"Br J Haematol"},{"issue":"5","key":"3460_CR82","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bjh.17023","volume":"191","author":"JM Rodrigues","year":"2020","unstructured":"Rodrigues JM, Hassan M, Freiburghaus C, Eskelund CW, Geisler C, Raty R et al (2020) p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Br J Haematol 191(5):796\u2013805. https:\/\/doi.org\/10.1111\/bjh.17023","journal-title":"Br J Haematol"},{"issue":"5","key":"3460_CR83","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3324\/haematol.2019.243071","volume":"106","author":"L Wang","year":"2021","unstructured":"Wang L, Tang G, Medeiros LJ, Xu J, Huang W, Yin CC et al (2021) MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica 106(5):1381\u20131389. https:\/\/doi.org\/10.3324\/haematol.2019.243071","journal-title":"Haematologica"},{"issue":"1","key":"3460_CR84","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00428-021-03022-8","volume":"479","author":"SM Aukema","year":"2021","unstructured":"Aukema SM, Croci GA, Bens S, Oehl-Huber K, Wagener R, Ott G et al (2021) Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. Virchows Arch 479(1):133\u2013145. https:\/\/doi.org\/10.1007\/s00428-021-03022-8","journal-title":"Virchows Arch"},{"issue":"1","key":"3460_CR85","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000505","volume":"5","author":"J Cheng","year":"2021","unstructured":"Cheng J, Hashem MA, Barabe F, Cloutier S, Xi L, Raffeld M et al (2021) CCND1 genomic rearrangement as a secondary event in high grade B-cell lymphoma. Hemasphere 5(1):e505. https:\/\/doi.org\/10.1097\/HS9.0000000000000505","journal-title":"Hemasphere"},{"issue":"9","key":"3460_CR86","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.3324\/haematol.2015.123885","volume":"100","author":"M Lord","year":"2015","unstructured":"Lord M, Wasik AM, Christensson B, Sander B (2015) The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes. Haematologica 100(9):e369-372. https:\/\/doi.org\/10.3324\/haematol.2015.123885","journal-title":"Haematologica"},{"issue":"3","key":"3460_CR87","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3324\/haematol.2019.219543","volume":"105","author":"B Federmann","year":"2020","unstructured":"Federmann B, Frauenfeld L, Pertsch H, Borgmann V, Steinhilber J, Bonzheim I et al (2020) Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression. Haematologica 105(3):754\u2013764. https:\/\/doi.org\/10.3324\/haematol.2019.219543","journal-title":"Haematologica"},{"issue":"4","key":"3460_CR88","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","volume":"132","author":"G Clot","year":"2018","unstructured":"Clot G, Jares P, Gine E, Navarro A, Royo C, Pinyol M et al (2018) A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood 132(4):413\u2013422. https:\/\/doi.org\/10.1182\/blood-2018-03-838136","journal-title":"Blood"},{"issue":"2","key":"3460_CR89","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41375-021-01389-w","volume":"36","author":"R Vilarrasa-Blasi","year":"2022","unstructured":"Vilarrasa-Blasi R, Verdaguer-Dot N, Belver L, Soler-Vila P, Beekman R, Chapaprieta V et al (2022) Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Leukemia 36(2):583\u2013587. https:\/\/doi.org\/10.1038\/s41375-021-01389-w","journal-title":"Leukemia"},{"issue":"5","key":"3460_CR90","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","volume":"34","author":"A Navarro","year":"2020","unstructured":"Navarro A, Bea S, Jares P, Campo E (2020) Molecular pathogenesis of mantle cell lymphoma. Hematol Oncol Clin North Am 34(5):795\u2013807. https:\/\/doi.org\/10.1016\/j.hoc.2020.05.002","journal-title":"Hematol Oncol Clin North Am"}],"updated-by":[{"DOI":"10.1007\/s00428-023-03488-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000}}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03460-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03460-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03460-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:22:55Z","timestamp":1674847375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03460-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3460"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03460-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00428-023-03488-8","asserted-by":"object"}]},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00428-023-03488-8","URL":"https:\/\/doi.org\/10.1007\/s00428-023-03488-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an invited review and contains no experiments for which ethical permissions are needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}